

Provider Update

November 23, 2021

DOH Deputy Secretary Laura C. Parajón, M.D., M.P.H
Infectious Disease Bureau Chief Dan Burke
NW Regional Health Officer Miranda Durham, M.D.

NM DOH Mission

To ensure health equity, we work with our partners to promote health and well-being, and improve health outcomes for all people in New Mexico.

Goals



We expand equitable access to services for all New Mexicans



We ensure safety in New Mexico healthcare environments




We improve health status for all New Mexicans



We support each other by promoting an environment of mutual respect, trust, open communication, and needed resources for staff to serve New Mexicans and to grow and reach their professional goals

COVID-19 Overview

Daily Trends in Number of Cases and COVID-19 Nucleic Acid Amplification Tests (NAATs) 7-day Percent Positivity in New Mexico Reported to CDC



DAILY NEW CASES


• **67.2** PER 100K

INFECTION RATE

• **1.14**

POSITIVE TEST RATE

• **14.0%**




On average, each person in New Mexico with COVID is infecting 1.14 other people. As such, the total number of active cases in New Mexico is growing. [About this data](#)


Share

Vaccine progress update

- **85%** of New Mexicans (18+) and 64.2% (12-17) have received at least a first dose
- **74.1%** of New Mexicans (18+) and 55.4% (12-17) are fully vaccinated
- **20.4%** of New Mexicans (18+) have received a booster dose (12-17 are not yet eligible)
- **12.7%** of 5 - 11 year olds have had at least a first dose



State-wide Progress for ages 5 - 11




Week ending:	Weekly relative increase For "At Least 1 Dose"	Weekly relative increase for Fully VAX
11/19	416 %	0
11/12		


15K doses last week

***Includes doses from the Indian Health Service, Veterans Administration, Department of Defense, Bureau of Prisons, and doses from other states administered to New Mexico residents

Weekly COVID-10 Vaccines Administered in NM since 12/24/20



Daily Count of Total Doses Administered and Reported to CDC by Date Administered, New Mexico



TOTAL VACCINE
DOSES
ADMINISTERED
US vs NM

Select a Location:

New Mexico

Metric:

- ☒ Total Doses Administered
- ☐ People Receiving Dose 1
- ☐ People Fully Vaccinated

View:

- ☒ Daily Count
- ☐ Cumulative
- ☐ Daily Change Reported

Show:

- ☒ 7-Day moving average
- ☒ US 7-Day moving average

Booster Updates



Boosters for people vaccinated outside the US

Pfizer - Emergency Use Instructions (issued 11/17/21)

People who completed all of the recommended doses of an WHO-EUL COVID-19 vaccine⁴ not approved or authorized by FDA, or people who completed a heterologous (mix and match) series composed of any combination of FDA-approved, FDA-authorized, or WHO-EUL COVID-19 vaccines:

- Are considered [fully vaccinated](#).
- Under the [EUI](#), moderately or severely immunocompromised people aged ≥ 12 years should receive an additional primary dose of Pfizer-BioNTech COVID-19 vaccine (30 μ g formulation [purple cap]) at least 28 days after receiving the second vaccine dose of their primary series as detailed in [Considerations for COVID-19 vaccination in moderately or severely immunocompromised people](#).
- Under the [EUI](#), people aged ≥ 18 years (including moderately or severely immunocompromised people who received an additional primary dose) are eligible to receive a single booster dose of Pfizer-BioNTech COVID-19 vaccine (30 μ g formulation [purple cap]) at least 6 months after completing their primary series, as detailed in [Considerations for use of a COVID-19 vaccine booster dose](#).

CDC authorizes boosters for 18+ (11/19/21)

Everyone Ages 18 and Older Can Get a Booster Shot

IF YOU RECEIVED

Pfizer-BioNTech or Moderna

You should get a booster if you are:

- Ages 50 years and older
- Ages 18 years and older and live in a [long-term care setting](#)

You may get a booster if you are:

- Ages 18 years and older

When to get a booster:

At least 6 months after completing your primary COVID-19 vaccination series

Which booster should you get?

[Any of the COVID-19 vaccines](#) authorized in the United States

IF YOU RECEIVED

Johnson & Johnson's Janssen

You should get a booster if you are:

- [18 years or older](#)

When to get a booster:

At least 2 months after your shot.

Which booster should you get?


[Any of the COVID-19 vaccines](#) authorized in the United States can be used for the booster dose.

Assessing Risk/Benefit for Boosters

- *Risk of exposure to SARS-CoV-2:* Factors that would be expected to affect the risk of exposure to SARS-CoV-2 include work or residence in [certain settings](#); [level of community transmission](#); [rates of COVID-19 vaccination in their community](#); the likelihood of frequent interactions with possibly unvaccinated people from outside an individual's household; and adherence to [current prevention measures](#).
- *Risk for developing SARS-CoV-2 infection:* A person's risk for developing SARS-CoV-2 infection may vary based on [time from completing a primary COVID-19 vaccine series](#) and [time from prior SARS-CoV-2 infection](#) due to waning immunity. Serologic testing or cellular immune testing is not recommended as part of the individual risk benefit assessment.
- *Risk for severe infection related to underlying conditions:* A person's risk of developing severe COVID-19 may vary by the type, number, and level of control of specific medical conditions as well as other yet to be defined variables. [Pregnant people](#) may receive a COVID-19 vaccine booster. Separately, also see section on [Considerations for COVID-19 vaccination in moderately or severely immunocompromised people](#).
- *Potential impact of SARS-CoV-2 infection:* SARS-CoV-2 infections that are not severe may still lead to morbidity (e.g., post-COVID-19 symptoms). A person's individual circumstances should also be considered; these may include living with/caring for a person who is medically frail or immunocompromised or a child who is not eligible for COVID-19 vaccine or the inability to work or meet other personal obligations when infected, even if not severely ill with COVID-19

[Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)

Booster Doses (includes Additional Doses) since 8.1.21




17% increase over last week

Boosters Progress by Primary Series

	Pfizer	Moderna	J&J	Total
Those vaccinated prior to this date are eligible for booster	5/24/2021	5/24/2021	9/23/2021	
Number who completed vax prior to ELIGIBILITY date	485,634	402,683	92,928	1,203,515
Number who have received booster to date	217,670	132,330	3,300	353,300
Percent of Eligible who have received a booster	45%	33%	4%	36%
last week:	40%	25%	3%	31%

COVID19 Vaccines for 5-11 Year-olds

Vaccination Progress for Ages 5-11 and 12-15






Data are drawn from the New Mexico State Immunization Information System (NMSIIS) and Tiberius and include only residents of New Mexico.

What percentage of people in each age range received the COVID-19 vaccine? ⓘ

Percent of people by age receiving **at least one dose** or **fully vaccinated**.

According to the Centers for Disease Control and Prevention, there is age information for **99%** of people who received **at least one dose** and **99%** of **fully vaccinated** people.



Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation
	<i>Dilute Prior to Use</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	5 to <12 years**
Vial Cap Color	PURPLE 	ORANGE 
Dose	30 mcg	10 mcg
Injection Volume	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions		
ULT Freezer (-90°C to -60°C)	9 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks

Pfizer 5-11 (Orange Cap) is a different NDC.

Please be careful when ordering Pfizer to select the correct PED vaccine

Pfizer 12+ can be ordered with PED ancillary supply kits but it is not Pfizer PED vaccine

Vaccine Messaging update

FEMA's COVID-19 Funeral Assistance Program

- If a loved one has died due to COVID 19—even if the deceased was undocumented—you might be eligible to receive financial help for their funeral expenses (including services, cremations, headstones, and more)
- Average aid = more than \$5,000 per NM registrant
- Available to US citizens, non-citizen nationals, and qualified aliens.



Call 844-684-6333 | TTY: 800-462-7585
To learn more, visit: COVID-19 Funeral Assistance |
FEMA.gov.

Programa de asistencia para gastos fúnebres COVID-19 de FEMA

- Si un ser querido ha fallecido a causa de COVID-19 (incluso si el fallecido era indocumentado) puede ser elegible para recibir ayuda financiera para sus gastos funerarios (incluyendo servicios, cremaciones, lápidas y más).
- Ayuda promedio = más de \$5,000 por solicitante de NM
- Disponible para los ciudadanos estadounidenses, aquellos que no son ciudadanos y extranjeros cualificados.



Llame al 844-684-6333 | TTY: 800-462-7585
Para obtener más información, visite asistencia para
gastos fúnebres COVID-19 | FEMA.gov.

Personal responsibilities

Shared responsibilities

Physical distance,
stay home if sick


Hand hygiene,
cough etiquette

If crowded,
limit your time

Ventilation, outdoors,
air filtration

Quarantine
and isolation

boosters



Antivirals Update

Molnupiravir (Merck oral antiviral) is first anticipated oral antiviral product.

- Indicated for adult patients with high risk of progression to severe disease.
- Must be given within 5 days of symptom onset.
- Patient course is 5 day
- Tentative 11/30/21 availability date
- Limited supply - allocated pro rata by state
 - Planning for both 100K and 400K doses nationally (600 - 2400 doses for NM)
 - MAT team working on allocation framework

ALL INFORMATION FOR PLANNING ONLY- PENDING EUA



Multiple PrEP therapies close to emergency use authorization.

AZD7442 is first anticipated product.

- Indicated for severely immunocompromised people and not expected to mount immune response to COVID-19 vaccines or those for whom COVID-19 vaccine is contraindicated.
- Combo of 2 long acting MABS
- IM injection
- Repeat dosing anticipated ~ 6 months
- Tentative 11/30/21 availability date

ALL INFORMATION FOR PLANNING ONLY-PENDING EUA

UPDATES from the Immunization Team

Redistribution: trying to decrease the amount of redistribution

Due to the Holiday please **submit orders in NMSIIS by Tuesday, 11/23 for delivery of 11/29**, this includes Pfizer ADU/PED, Moderna, and J&J

Because we are no longer in an unlimited supply situation, specifically **Moderna**, we ask you to please:

- Be **efficient** with opening vials and try to group patients together to minimize waste (we know this contradicts earlier messages).
- Remember to offer **Pfizer** as a booster option.
- Please be sure to **update inventory in NMSIIS and Vaccine Finder within 24hrs, this is required per CDC COVID vaccine program enrollment**. When CDC sees we have more inventory on the books than we really have they don't allocate as many doses as we need.



For assistance:

1. contact our NMSIIS Help Desk at (833) 882-6454
2. email us at COVID.vaccines@state.nm.us
3. resource guide in the NMSIIS Reports section



QR Codes:

- ❑ QR Codes will be back on immunization records pulled from NMSIIS starting next week (we hope).
- ❑ The QR codes will be visible on immunization records pulled from the public portal Vaxviewnm.org (state.nm.us) in **January**.
- ❑ Stay tuned for a QR code resource guide.






CDC Updates

Interim Clinical Considerations for Use of COVID-19
Vaccines Currently Approved or Authorized in the
United States: [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)

RTS Updates

- Digital consent for children under 18
- Electronic consent - need to be logged into the parent profile to sign



Questions: covid.vaccines@state.nm.us



Thank you for all that you do!